Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Recommending A Patient-Level Study To Confirm That Bcg Vaccination Accounts For The Relatively Low Covid-19 Mortality Rate In The Philippines, Amulfo P. Azcarraga
Recommending A Patient-Level Study To Confirm That Bcg Vaccination Accounts For The Relatively Low Covid-19 Mortality Rate In The Philippines, Amulfo P. Azcarraga
Angelo King Institute for Economic and Business Studies (AKI)
Medical researchers have pointed out wide differences in COVID-related death rates among countries; and several explanations have been offered such as the high number of old people in a country, number of tourists, number of immigrants, geographic location and climate, size of the population, etc. One possible explanation that deserves further study is that countries where the COVID death rate is low are those countries where mass BCG vaccination is in place, such as the Philippines. Indeed, compared to countries who have never had mass BCG vaccination, i.e. USA, Canada, Italy, Netherlands and Belgium, the death rate due to COVID-19 …
Preparing For Shortages Of Future Covid-19 Drugs: A Data-Based Model For Optimal Allocation, Charlie L. Sy, Kathleen Aviso, Christina D. Cayamanda, Anthony F. Chiu, Rochelle Irene Lucas, Michael Angelo Promentilla, Luis F. Razon, Raymond R. Tan, John Frederick Tapia, Ador Torneo, Aristotle T. Ubando, Derrick Ethelbhert C. Yu
Preparing For Shortages Of Future Covid-19 Drugs: A Data-Based Model For Optimal Allocation, Charlie L. Sy, Kathleen Aviso, Christina D. Cayamanda, Anthony F. Chiu, Rochelle Irene Lucas, Michael Angelo Promentilla, Luis F. Razon, Raymond R. Tan, John Frederick Tapia, Ador Torneo, Aristotle T. Ubando, Derrick Ethelbhert C. Yu
Angelo King Institute for Economic and Business Studies (AKI)
Drugs for the treatment of Covid-19 are currently beign tested, and those that are apporved for use are likely to be in short supply due to the global scale of the pandemic. This policy brief proposes a model for optimally allocating future Covid-19 drugs to patients to minimize deaths under conditions of resource scarcity. A linear programming model is developed that estimates the potential number of deaths that may result from Covid-19 under two scenarios: with antivirals and without antivirals. It takes into account patient risk level, the severity of their symptoms, resource availability in hospitals (i.e. hospital beds, critical …